Malaga, Spain - April 17, 2016 - Today, at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, an international research team presented the preliminary results of a new study which aimed to determine whether the predictive value of a past major osteoporotic fracture (MOF) for future MOF changed with time.
They studied a database of 118,872 men and women born between 1907 and 1935 who were part of the Reykjavik Study during 1967-1991. Data on all fractures from participant entry into the study until December 31, 2012 were extracted.
Of the 5039 patients who experienced one or more major osteoporotic fractures and were included in the analysis, 1919 patients experienced a second fracture. The analysis showed:
- The risk of a second major osteoporotic fracture after a first increased by 4% for each year of age and was 41% higher for women than men.
- The risk of a second major osteoporotic fracture was greatest immediately after the first fracture. Although the risk thereafter decreased with time, it remained higher than the population risk throughout follow-up.
One year after the first major osteoporotic fracture the risk of a second fracture was 3 times higher than that risk amongst those who had not experienced a fracture. After 10 years this risk was still elevated, at 2 times the risk in the non-fracture population but was lower than at one year.
Presenting author Prof. Nicholas C. Harvey of the MRC Lifecourse Epidemiology Unit, University of Southampton, stated, "The results of our study show that the risk of further fracture after a first major osteoporotic fracture is greatest immediately following the first event, with a declining, but still increased, risk in subsequent years. These results suggest that pharmacological treatment for secondary fracture prevention should be considered during the period immediately following a first fracture."
The results of this study support international efforts to promote secondary fracture prevention in clinics worldwide. Studies have shown that half of all individuals who suffer a hip fracture have already come to clinical attention because of a prior fragility fracture. All too often the broken bone is simply 'repaired' and the patient is sent home without proper diagnosis and management of the underlying cause of the first fracture. It is estimated that approximately 80% of patients who suffer a first fracture are never diagnosed and treated. In order to address this serious problem, the implementation of coordinated systems of secondary fracture prevention has become a major health-policy focus of the International Osteoporosis Foundation (IOF) through its Capture the Fracture® initiative: http://www.
OC35 Imminent Risk of Major Osteoporotic Fracture After Fracture (Reykjavik Study)
N. C. Harvey, H. Johansson, K. Siggeirsdottir, A. Oden, V. Gudnason, E. McCloskey, G. Sigurdsson, J. A. Kanis
Abstract book: WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, 14 -17 April 2016, Malaga, Spain Osteoporosis International, Volume 27/ Suppl 1/ 2016
About World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO 2016):
Held jointly by IOF and ESCEO, the Congress is taking place in Malaga, Spain from April 14-17,2016. It is the world's largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including sarcopenia and frailty. The next Congress will be held in Florence, Italy from March 23-26, 2017. For complete information visit http://www.
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers, leading companies, as well as more than 234 patient, medical and research societies in 99 locations, work together to make bone, joint and muscle health a worldwide heath care priority. http://www.
The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. http://www.